Florent G.
- Country
- France
- Department
- Hépato-gastro-entérologie
Research Overview
- Efficacy and Safety of Upadacitinib in Maintenance and Long-Term Extension for Crohn's Disease Post-Induction Responders
- Evaluation of Guselkumab Subcutaneous Induction Therapy Efficacy and Safety in Moderate to Severe Ulcerative Colitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
- Efficacy and Safety Evaluation of RO7790121 Induction Therapy in Moderately to Severely Active Ulcerative Colitis: A Phase III Multicenter Double-Blind Placebo-Controlled Study
Data & Insights
Has run more than one trial at 33 of 180 partner sites.
Specializations
Inflammatory Bowel Disease
Florent Gonzalez is involved in clinical research focused on Crohn's disease and ulcerative colitis, with an emphasis on patients living with moderate to severe disease activity. The therapeutic landscape includes biologic and targeted treatment strategies aimed at controlling intestinal inflammation and improving disease control in gastroenterology.
- Moderately to severely active Crohn's disease
- Moderately to severely active ulcerative colitis
- Advanced anti-inflammatory therapies
His trial portfolio reflects work in both induction and longer-term treatment settings within immune-mediated bowel disease.
Targeted Therapy in Crohn's Disease
His research activity includes evaluation of modern targeted agents for Crohn's disease, particularly in patients who have not responded adequately to prior anti-TNF therapy. The clinical focus is on therapies designed to support symptom control, remission, and sustained disease management.
- Risankizumab
- Upadacitinib
- Long-term safety and maintenance treatment
This area highlights interest in both biologic and JAK inhibitor approaches for chronic inflammatory bowel disease.
Ulcerative Colitis Therapeutics
Florent Gonzalez is also engaged in studies of induction therapy for ulcerative colitis, with attention to patients presenting with moderate to severe active disease. The therapeutic domain centers on agents intended to induce clinical remission and improve disease outcomes in colonic inflammation.
- Guselkumab
- RO7790121
- Induction treatment strategies
His work in this field contributes to the expanding range of targeted immunotherapy options for ulcerative colitis.
Antithrombotic Therapy in Valvular Heart Disease
His research portfolio extends beyond gastroenterology to include valvular heart disease in patients with a recently implanted aortic bioprosthesis. The clinical interest is centered on antithrombotic treatment and prevention of thromboembolic complications after bioprosthetic aortic valve replacement.
- Apixaban
- Aspirin
- Valve thrombosis prevention
This activity places him at the intersection of cardiovascular thrombosis and postoperative valve care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.